21 results on '"Heininger D"'
Search Results
2. Temperature effects on malic-acid efflux from the vacuoles and on the carboxylation pathways in Crassulacean-acid-metabolism plants
- Author
-
Friemert, V., Heininger, D., Kluge, M., and Ziegler, H.
- Published
- 1988
3. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab
- Author
-
Riedl, M., Hofer, J., Giner, T., Rosales, A., Häffner, K., Simonetti, G.D., Walden, U., Maier, T., Heininger, D., Jeller, V., Weiss, G., Heuvel, L.P. van den, Zimmerhackl, L.B., Würzner, R., Jungraithmayr, T.C., Riedl, M., Hofer, J., Giner, T., Rosales, A., Häffner, K., Simonetti, G.D., Walden, U., Maier, T., Heininger, D., Jeller, V., Weiss, G., Heuvel, L.P. van den, Zimmerhackl, L.B., Würzner, R., and Jungraithmayr, T.C.
- Abstract
Item does not contain fulltext
- Published
- 2016
4. REGENERATION OF EFFECTOR FUNCTION IN VITRO
- Author
-
Clark, W.R., primary, Heininger, D., additional, Touton, M., additional, and Chakravarty, A.K., additional
- Published
- 1977
- Full Text
- View/download PDF
5. LIST OF CONTRIBUTORS
- Author
-
ABELL, C.W., primary, ALFORD, ROBERT H., additional, ALTER, B.J., additional, ANDERSON, A.O., additional, ANDERSON, DEBORAH J., additional, ANDERSON, SUSAN M., additional, ANDRON, L.A., additional, ANTON, ELIZABETH, additional, ARALA-CHAVES, M.P., additional, ARNON, R., additional, ASCHER, M.S., additional, BACH, F.H., additional, BAIRD, LYNN G., additional, BARCINSKI, MARCELLO A., additional, BARKER, BARBARA E., additional, BARTH, ROLF F., additional, BATTISTO, JACK R., additional, BELL, CLARA, additional, BEN-SASSON, SHMUEL A., additional, BERKE, GIDEON, additional, BERNHEIM, JAN L., additional, BESSLER, WOLFGANG G., additional, BETEL, IDO, additional, BETZ, SALLY J., additional, BEYER, C.F., additional, BLAESE, R. MICHAEL, additional, BLANKWATER, M.J., additional, BOCHERT, G., additional, BOCKMAN, D.E., additional, BOLDT, DAVID H., additional, BONA, CONSTANTIN, additional, BONAVIDA, BENJAMIN, additional, BONNARD, GUY D., additional, BOREL, J.F., additional, BOWERS, W.E., additional, BRAATZ, J.A., additional, BRADLEY, B., additional, BRADLEY, B.A., additional, BRAUNSTEINER, HERBERT, additional, BRODER, S., additional, BROWN, JOHN M., additional, BUNDY, BONITA M., additional, BURGER, D.R., additional, CAMBELL, D.A., additional, CARPENTER, C.B., additional, CASTAGNOLA, JAN, additional, CAVILES, ALENDRY P., additional, CHAKRAVARTY, A.K., additional, CHAPLIN, D.D., additional, CHARMOT, D., additional, CHISARI, F.V., additional, CLARK, W.R., additional, CLEMENTS, PHILIP J., additional, COHEN, I.R., additional, COOPER, HERBERT L., additional, COOPER, M.D., additional, COOPER, R.A., additional, CORLEY, RONALD B., additional, CROSIER, P., additional, CUNNINGHAM-RUNDLES, S., additional, CURTISS, LINDA K., additional, DANIELE, RONALD P., additional, DARAI, G., additional, DAUSSET, J., additional, DAVID, JOHN R., additional, DAYNES, RAYMOND A., additional, DEAN, JACK H., additional, DEBATES, MARY JO, additional, DECKER, JEAN M., additional, DE GOEDE, R.E.Y, additional, DEHEER, DAVID H., additional, DELFRAISSY, J.F., additional, DEWOLF, W.C., additional, DOOLEY, N.D., additional, DOOLEY, NANCY J., additional, DORIAN, RANDEL, additional, DORMONT, J., additional, DOUGLAS, GARY N., additional, DRAY, SHELDON, additional, DUPONT, B., additional, DURM, M., additional, DWYER, JOHN M., additional, EDGINGTON, THOMAS S., additional, ELFERINK, DIENNE, additional, ENDRES, ROBERT O., additional, ESSELMAN, WALTER J., additional, FAGAN, G., additional, FARNES, PATRICIA, additional, FAUCI, ANTHONY S., additional, FERGUSON, RONALD M., additional, FERRARINI, M., additional, FLETCHER, MARK P., additional, FRELINGER, JEFFREY A., additional, FORSDYKE, D.R., additional, FROST, A.F., additional, FUDENBERG, H. HUGH, additional, GALANAUD, P., additional, GAROVOY, M.R., additional, GARRIDO, F., additional, GEHA, RAIF S., additional, GEMSA, DIETHARD, additional, GEORGE, K., additional, GERSHWIN, M. ERIC, additional, GLICKMAN, E., additional, GOLDBLUM, R.M., additional, GOLDMAN, C., additional, GOLDSTEIN, ALLAN L., additional, GOOD, R.A., additional, GORDON, DAVID S., additional, GORDON, G., additional, GORDON, IAN L., additional, GORDON, JULIUS, additional, GORENBERG, DAVID J., additional, GORSKA, R., additional, GORSKI, A.J., additional, GOTTLIEB, M.N., additional, GRANBERG, CHRISTER, additional, GRANGER, GALE A., additional, GRAYBILL, J. RICHARD, additional, GREY, HOWARD M., additional, GRILLOT-COURVALIN, C., additional, GRIMM, ELIZABETH ANN, additional, GRINWICH, KAZIMIERA, additional, GROSSI, C.E., additional, GüNTHER, EBERHARD, additional, GUERRY, D., additional, HAMILL, BARBARA, additional, HANSEN, J.A., additional, HANTKE, KLAUS, additional, HAYWARD, A.R., additional, HEININGER, D., additional, HELDERMAN, J. HAROLD, additional, HENKART, PIERRE A., additional, HENNEY, CHRISTOPHER H., additional, HERBERMAN, R.B., additional, HESTER, RAYMOND B., additional, HIRSCHBERG, HENRY, additional, HISERODT, JOHN C., additional, HOETTE, M., additional, HOLIMAN, B.J., additional, HORSMANHEIMO, A., additional, HORSMANHEIMO, M., additional, SUNY, MICHAEL L. HOWE, additional, HUBER, CHRISTOPH, additional, HURTUBISE, P.E., additional, IKEDA, RICHARD, additional, ITZCHAKI, M., additional, JACOBS, DIANE M., additional, JANICKI, BERNARD W., additional, JARRETT-TOTH, E., additional, JENSEN, PAMELA, additional, JERRY, L. MARTIN, additional, JONES, THOMAS B., additional, JONGENEEL, C. VICTOR, additional, JUNGFER, H., additional, KACENA, AMELIA, additional, KALDANY, A., additional, KAPLAN, ALAN M., additional, KAPLAN, J.G., additional, KASHKET, EVA R., additional, KAY, H. DAVID, additional, KAZURA, J., additional, KEARNEY, J.K., additional, KERMANI-ARAB, V., additional, KIERSZENBAUM, F., additional, KEYSSNER, K., additional, KIRCHNER, H., additional, KIRKPATRICK, CHARLES H., additional, KLEIN, J., additional, KLIMPEL, GARY, additional, KOLB, W.P., additional, KORN, J., additional, KOSKI, L.J., additional, KRAKAUER, R., additional, KRUISBEEK, ADA M., additional, KRUITHOF, E.K.O., additional, KUBO, RALPH T., additional, LANOTTE, M., additional, LAUGHTER, ARLINE H., additional, LAUGHTER, BARBARA J., additional, LA VIA, D.S., additional, LA VIA, M.F., additional, LAWRENCE, E.C., additional, LAWTON, A.R., additional, LEGRAND, L., additional, LEON, MYRON A., additional, LESLIE, G.A., additional, UCLA, JOSHUA LEVY, additional, LICHTMAN, M.A., additional, LIFTON, J., additional, LIGHTBODY, JAMES J., additional, LINKER-ISRAELI, M., additional, LOPATIN, DENNIS E., additional, LORARCHER, ALOIS, additional, LORD, EDITH M., additional, LUCAS, DAVID O., additional, LUCAS, KEES, additional, LUNDIN, A.P., additional, LYDYARD, P.M., additional, MCCALMON, ROBERT T., additional, MACDERMOTT, RICHARD P., additional, MCDOUGAL, J.S., additional, MCINTIRE, K.R., additional, MACKLER, BRUCE F., additional, MADYASTHA, K.R., additional, MADYASTHA, P.R., additional, MÄHLER, BERND, additional, MAKI, TAKASHI, additional, MANNINEN, KIMMO, additional, MARTIJNSE, JOKE, additional, MAWAS, C., additional, MAYER, EUGENE P., additional, MEADE, B., additional, MENDELSOHN, JOHN, additional, MENZEL, J., additional, MERGENHAGEN, S.E., additional, METZGER, JOACHIM, additional, MILLER, GINGER W., additional, MILLER, HAROLD C., additional, MILLER, J., additional, MILLS, G., additional, MINGARI, M.C., additional, MOERMAN, C., additional, MOLDOW, C.F., additional, MONAHAN, T.M., additional, MORETTA, A., additional, MORETTA, L., additional, MORRISON, DAVID C., additional, MOTICKA, EDWARD J., additional, MUCHMORE, ANDREW V., additional, MULLER-EBERHARD, H.J., additional, MUNK, K., additional, MUUL, L., additional, NASH, GEOFFREY S., additional, NEGENDANK, W., additional, NELSON, DAVID L., additional, NELSON, J.A., additional, NETA, R., additional, NEWELL, LAURIE, additional, NG, A.K., additional, O'BRIEN, RICHARD L., additional, OEHLER, J.R., additional, O'NEILL, PEGGY A., additional, OPPENHEIM, JOOST J., additional, ORTALDO, J.R., additional, PAHWA, S., additional, PANIJEL, J., additional, PAPE, GERD R., additional, PARADYSZ, J., additional, PARKER, C.W., additional, PARKER, JOHN W., additional, PARRILLO, JOSEPH E., additional, PAWELEC, G.P., additional, PEARSON, CARL M., additional, PERLMANN, PETER, additional, PILARSKI, LINDA M., additional, PLATA, FERNANDO, additional, PLESCIA, ANNE M., additional, PLESCIA, OTTO J., additional, PONZIO, N.M., additional, POPLACK, D.G., additional, PRATT, KAREN R., additional, PUNTIS, M.C.A, additional, RANNEY, DAVID F., additional, RASMUSSEN, HOWARD, additional, REDELMAN, DOUG, additional, RESCH, KLAUS, additional, RICH, ROBERT R., additional, RICH, SUSAN SOLLIDAY, additional, ROBERTS, R.L., additional, RODE, HAROLD N., additional, ROSENSTREICH, DAVID L., additional, ROSENTHAL, ALAN S., additional, ROSSIO, JEFFREY L., additional, ROWDEN, GEOFFREY, additional, ROWLAND, GEORGE, additional, RUBIN, ARNOLD S., additional, RüDE, ERWIN, additional, RüHL, H., additional, RüHL, U., additional, RYAN, JOHN L., additional, SALVIN, S.B., additional, SASPORTES, M., additional, SCHIRRMACHER, V., additional, SCHMALSTIEG, F.C., additional, SCHMIDTKE, JON R., additional, SCHOLLE, H., additional, SCHRIEBER, A.D., additional, SCHUBERT, RICHARD D., additional, SEGEL, G.B., additional, SELL, STEWART, additional, SHALLER, C., additional, SHARON, N., additional, SHEA, MARY, additional, SHEEHAN, JAMES M., additional, SHEPPARD, HAYNES W., additional, SHEPPARD, J.R., additional, SHERIDAN, JOHN, additional, SHEVACH, ETHAN M., additional, SHIFRINE, M., additional, SHIFTAN, THOMAS A., additional, SHORE, STEVEN L., additional, SIMMONS, RICHARD L., additional, SMITH, ALAN, additional, SMITH, TERRILL K., additional, SOULILLOU, J.P., additional, SPECKART, STEPHEN F., additional, SPELLMAN, CRAIG W., additional, STEGGEMANN, LUDWIG, additional, STEINMAN, L., additional, STEJSKAL, VERA, additional, STEWART, CARLETON C., additional, STITES, DANIEL P., additional, ST. LOUIS, G., additional, STOBO, J.D., additional, STOECK, MICHAEL, additional, STRAUSS, PHYLLIS R., additional, STROBER, W., additional, STROM, TERRY B., additional, SULLIVAN, ARTHUR K., additional, SUNDSMO, J.S., additional, SUTCLIFFE, MARILYN C., additional, SUTHANTHIRAN, M., additional, SWART, A.C.W., additional, TAYLOR, CLIVE R., additional, TEITELBAUM, D., additional, TEODORESCU, MARIUS, additional, TERMIJTELEN, A., additional, THESTRUP-PEDERSEN, KRISTIAN, additional, LE THI, HIEN, additional, THOMAS, DAVID W., additional, THORBECKE, G.J., additional, THORSBY, ERIK, additional, THURMAN, GARY B., additional, TILL, GERD, additional, TILNEY, N.L., additional, TOIVANEN, PAAVO, additional, TOMASI, THOMAS B., additional, TOUTON, M., additional, TRAININ, N., additional, TREFTS, PARK E., additional, TROWBRIDGE, SIDNEYE, additional, TRUFFA-BACHI, PAULO, additional, UBELS-POSTMA, JOSÉ, additional, UMIEL, T., additional, VAN BEKKUM, D.W., additional, VAN DE BERG, TINEKE, additional, VAN DEN TWEEL, JAN G., additional, VAN DEN WESTEN, GERARD, additional, VAN HEES, MARITA, additional, VAN OERS, M.H.J., additional, VAN ROOD, J.J., additional, VOGT, W., additional, WAKSMAN, B.H., additional, WALDMANN, T.A., additional, WALKER, WILLIAM S., additional, WALLON, CH., additional, WARE, CARL F., additional, WEBB, S.R., additional, WEBER, W.T., additional, WEDNER, H.J., additional, WERNET, P., additional, WEST, WILLIAM H., additional, WHISLER, R.L., additional, WIESINGER, DOROTHEE, additional, WIGZELL, HANS, additional, WILCOX, C., additional, WILSON, F.D., additional, WINKELSTEIN, A., additional, WOOD, DAVID D., additional, WOODWARD, JEROLD G., additional, WRIGHT, S.C., additional, YEN, BELINDA, additional, YOSHIDA, TAKESHI, additional, YU, DAVID TAK YAN, additional, ZEIJLEMAKER, W.P., additional, ZICCA, A., additional, ZIER, KAREN, additional, and ZIMMERMANN, RITA, additional
- Published
- 1977
- Full Text
- View/download PDF
6. Normal response to pregnancy in rats cured of streptozotocin diabetes by transplantation of one fetal pancreas
- Author
-
Brown, J., Heininger, D., Kuret, J., and Mullen, Y.
- Published
- 1982
- Full Text
- View/download PDF
7. Cigarette smoking and chronic allograft nephropathy
- Author
-
Zitt, N., primary, Kollerits, B., additional, Neyer, U., additional, Mark, W., additional, Heininger, D., additional, Mayer, G., additional, Kronenberg, F., additional, and Lhotta, K., additional
- Published
- 2007
- Full Text
- View/download PDF
8. Islet cells grow after transplantation of fetal pancreas and control of diabetes.
- Author
-
Brown, Josiah, Heininger, Diane, Kuret, Jeffrey, Mullen, Yoko, Brown, J, Heininger, D, Kuret, J, and Mullen, Y
- Published
- 1981
- Full Text
- View/download PDF
9. The interferon-regulated host factor hnRNPA0 modulates HIV-1 production by interference with LTR activity, mRNA trafficking, and programmed ribosomal frameshifting.
- Author
-
Roesmann F, Sertznig H, Klaassen K, Wilhelm A, Heininger D, Heß S, Elsner C, Marschalek R, Santiago ML, Esser S, Sutter K, Dittmer U, and Widera M
- Subjects
- Humans, HEK293 Cells, Heterogeneous-Nuclear Ribonucleoproteins metabolism, Heterogeneous-Nuclear Ribonucleoproteins genetics, Host-Pathogen Interactions, Jurkat Cells, RNA Transport, RNA, Viral genetics, RNA, Viral metabolism, Frameshifting, Ribosomal, HIV Infections virology, HIV Infections genetics, HIV Infections metabolism, HIV Infections immunology, HIV Long Terminal Repeat genetics, HIV-1 physiology, HIV-1 genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Virus Replication
- Abstract
The interplay between host factors and viral components impacts viral replication efficiency profoundly. Members of the cellular heterogeneous nuclear ribonucleoprotein family (hnRNPs) have been extensively studied as HIV-1 host dependency factors, but whether they play a role in innate immunity is currently unknown. This study aimed to identify hnRNPA0 as a type I interferon (IFN)-repressed host factor in HIV-1-infected cells. Knockdown of hnRNPA0, a situation that mirrors conditions under IFN stimulation, increased LTR activity, export of unspliced HIV-1 mRNA, viral particle production, and thus, increased infectivity. Conversely, hnRNPA0 overexpression primarily reduced plasmid-driven and integrated HIV-1 long terminal repeat (LTR) activity, significantly decreasing total viral mRNA and protein levels. In addition, high levels of hnRNPA0 significantly reduced the HIV-1 programmed ribosomal frameshifting efficiency, resulting in a shift in the HIV-1 p55/p15 ratio. The HIV-1 alternative splice site usage remained largely unaffected by altered hnRNPA0 levels suggesting that the synergistic inhibition of the LTR activity and viral mRNA transcription, as well as impaired ribosomal frameshifting efficiency, are critical factors for efficient HIV-1 replication regulated by hnRNPA0. The pleiotropic dose-dependent effects under high or low hnRNPA0 levels were further confirmed in HIV-1-infected Jurkat cells. Finally, our study revealed that hnRNPA0 levels in PBMCs were lower in therapy-naive HIV-1-infected individuals compared to healthy controls. Our findings highlight a significant role for hnRNPA0 in HIV-1 replication and suggest that its IFN-I-regulated expression levels are critical for viral fitness allowing replication in an antiviral environment.IMPORTANCERNA-binding proteins, in particular, heterogeneous nuclear ribonucleoproteins (hnRNPs), have been extensively studied. Some act as host dependency factors for HIV-1 since they are involved in multiple cellular gene expression processes. Our study revealed hnRNPA0 as an IFN-regulated host factor, that is differently expressed after IFN-I treatment in HIV-1 target cells and lower expressed in therapy-naïve HIV-1-infected individuals. Our findings demonstrate the significant pleiotropic role of hnRNPA0 in viral replication: In high concentrations, hnRNPA0 limits viral replication by negatively regulating Tat-LTR transcription, retaining unspliced mRNA in the nucleus, and significantly impairing programmed ribosomal frameshifting. Low hnRNPA0 levels as observed in IFN-treated THP-1 cells, particularly facilitate HIV LTR activity and unspliced mRNA export, suggesting a role in innate immunity in favor of HIV replication. Understanding the mode of action between hnRNPA0 and HIV-1 gene expression might help to identify novel therapeutically strategies against HIV-1 and other viruses., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
10. SRSF1 acts as an IFN-I-regulated cellular dependency factor decisively affecting HIV-1 post-integration steps.
- Author
-
Sertznig H, Roesmann F, Wilhelm A, Heininger D, Bleekmann B, Elsner C, Santiago M, Schuhenn J, Karakoese Z, Benatzy Y, Snodgrass R, Esser S, Sutter K, Dittmer U, and Widera M
- Subjects
- Humans, Leukocytes, Mononuclear, Antibodies, RNA, Messenger, Serine-Arginine Splicing Factors genetics, HIV-1, HIV Seropositivity, Interferon Type I
- Abstract
Efficient HIV-1 replication depends on balanced levels of host cell components including cellular splicing factors as the family of serine/arginine-rich splicing factors (SRSF, 1-10). Type I interferons (IFN-I) play a crucial role in the innate immunity against HIV-1 by inducing the expression of IFN-stimulated genes (ISGs) including potent host restriction factors. The less well known IFN-repressed genes (IRepGs) might additionally affect viral replication by downregulating host dependency factors that are essential for the viral life cycle; however, so far, the knowledge about IRepGs involved in HIV-1 infection is very limited. In this work, we could demonstrate that HIV-1 infection and the associated ISG induction correlated with low SRSF1 levels in intestinal lamina propria mononuclear cells (LPMCs) and peripheral blood mononuclear cells (PBMCs) during acute and chronic HIV-1 infection. In HIV-1-susceptible cell lines as well as primary monocyte-derived macrophages (MDMs), expression levels of SRSF1 were transiently repressed upon treatment with specific IFNα subtypes in vitro. Mechanically, 4sU labeling of newly transcribed mRNAs revealed that IFN-mediated SRSF1 repression is regulated on early RNA level. SRSF1 knockdown led to an increase in total viral RNA levels, but the relative proportion of the HIV-1 viral infectivity factor (Vif) coding transcripts, which is essential to counteract APOBEC3G-mediated host restriction, was significantly reduced. In the presence of high APOBEC3G levels, however, increased LTR activity upon SRSF1 knockdown facilitated the overall replication, despite decreased vif mRNA levels. In contrast, SRSF1 overexpression significantly impaired HIV-1 post-integration steps including LTR transcription, alternative splice site usage, and virus particle production. Since balanced SRSF1 levels are crucial for efficient viral replication, our data highlight the so far undescribed role of SRSF1 acting as an IFN-modulated cellular dependency factor decisively regulating HIV-1 post-integration steps., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Sertznig, Roesmann, Wilhelm, Heininger, Bleekmann, Elsner, Santiago, Schuhenn, Karakoese, Benatzy, Snodgrass, Esser, Sutter, Dittmer and Widera.)
- Published
- 2022
- Full Text
- View/download PDF
11. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab.
- Author
-
Riedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, Walden U, Maier T, Heininger D, Jeller V, Weiss G, van den Heuvel L, Zimmerhackl LB, Würzner R, and Jungraithmayr TC
- Subjects
- Adult, Atypical Hemolytic Uremic Syndrome drug therapy, Atypical Hemolytic Uremic Syndrome immunology, Biomarkers metabolism, Complement C5 immunology, Complement Membrane Attack Complex metabolism, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunosuppression Therapy, Male, Middle Aged, Plasma metabolism, Antibodies, Monoclonal, Humanized therapeutic use, Atypical Hemolytic Uremic Syndrome diagnosis, Complement C5 metabolism, Immunotherapy methods
- Published
- 2016
- Full Text
- View/download PDF
12. The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
- Author
-
Huber JM, Tagwerker A, Heininger D, Mayer G, Rosenkranz AR, and Eller K
- Subjects
- Animals, Anti-Inflammatory Agents toxicity, Apoptosis drug effects, Boronic Acids administration & dosage, Bortezomib, CD4 Lymphocyte Count, Creatinine blood, Cyclin-Dependent Kinase Inhibitor p21 metabolism, Cytokines metabolism, Disease Models, Animal, Dose-Response Relationship, Drug, Injections, Intravenous, Kidney enzymology, Kidney immunology, Kidney pathology, Kidney Diseases enzymology, Kidney Diseases immunology, Kidney Diseases pathology, Male, Mice, Mice, Inbred C57BL, Necrosis, Nephritis enzymology, Nephritis immunology, Nephritis prevention & control, Protease Inhibitors administration & dosage, Proteasome Endopeptidase Complex metabolism, Pyrazines administration & dosage, Reperfusion Injury enzymology, Reperfusion Injury immunology, Reperfusion Injury pathology, Time Factors, Boronic Acids toxicity, Kidney drug effects, Kidney Diseases chemically induced, Protease Inhibitors toxicity, Proteasome Inhibitors, Pyrazines toxicity, Reperfusion Injury chemically induced
- Abstract
Bortezomib is a well-established treatment option for patients with multiple myeloma (MM). It is a selective and reversible inhibitor of the proteasome that is responsible for the degradation of many regulatory proteins that are involved in apoptosis, cell-cycle regulation, or transcription. Because patients with MM are prone to develop acute renal failure, we evaluated the influence of bortezomib on renal ischemia-reperfusion injury (IRI). Mice were subjected to renal IRI by having the renal pedicles clamped for 30 min followed by reperfusion for 3, 24, and 48 h. Mice were either pretreated with 0.5 mg/kg body wt bortezomib or vehicle intravenously 12 h before induction of IRI. Serum creatinine and tubular necrosis were significantly increased in bortezomib compared with vehicle-treated mice. The inflammatory response was found to be significantly decreased in bortezomib-treated mice as reflected by a decreased infiltration of CD4(+) T cells and a significantly decreased Th1 cytokine expression in the kidneys. In contrast, apoptosis was significantly increased in kidneys of bortezomib-treated mice compared with vehicle-treated controls. Increased numbers of TUNEL-positive cells/mm(2) and increased mRNA expression of proapoptotic factors were detected in kidneys of bortezomib-treated mice. Of note, p21, a cell senescence marker, was also significantly increased in kidneys of bortezomib-treated mice. In summary, we provide evidence that bortezomib worsens the outcome of renal IRI by leading to increased apoptosis of tubular cells despite decreased infiltrating T cells and proinflammatory mediators.
- Published
- 2009
- Full Text
- View/download PDF
13. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease.
- Author
-
Rudnicki M, Perco P, Enrich J, Eder S, Heininger D, Bernthaler A, Wiesinger M, Sarközi R, Noppert SJ, Schramek H, Mayer B, Oberbauer R, and Mayer G
- Subjects
- Basic Helix-Loop-Helix Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, Cohort Studies, Epidermal Growth Factor metabolism, Epithelial Cells metabolism, Gene Expression Profiling, Humans, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Immunohistochemistry, Insulin-Like Growth Factor I metabolism, Kidney metabolism, Kidney pathology, Kidney Diseases metabolism, Kidney Diseases pathology, Kidney Failure, Chronic genetics, Kidney Failure, Chronic metabolism, Kidney Failure, Chronic pathology, Kidney Tubules, Proximal cytology, Microdissection, Oligonucleotide Array Sequence Analysis, Signal Transduction, Vascular Endothelial Growth Factor A metabolism, p21-Activated Kinases genetics, p21-Activated Kinases metabolism, Cell Hypoxia physiology, Gene Expression Regulation, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Kidney Diseases genetics, Kidney Tubules, Proximal metabolism, Vascular Endothelial Growth Factor A genetics
- Abstract
Proteinuria, inflammation, chronic hypoxia, and rarefaction of peritubular capillaries contribute to the progression of renal disease by affecting proximal tubular epithelial cells (PTECs). To study the transcriptional response that separates patients with a stable course from those with a progressive course of disease, we isolated PTECs by laser capture microdissection from cryocut tissue sections of patients with proteinuric glomerulopathies (stable n=20, progressive n=11) with a median clinical follow-up of 26 months. Gene-expression profiling and a systems biology analysis identified activation of intracellular vascular endothelial growth factor (VEGF) signaling and hypoxia response pathways in progressive patients, which was associated with upregulation of hypoxia-inducible-factor (HIF)-1alpha and several HIF target genes, such as transferrin, transferrin-receptor, p21, and VEGF-receptor 1, but downregulation of VEGF-A. The inverse expression levels of HIF-1alpha and VEGF-A were significantly superior in predicting clinical outcome as compared with proteinuria, renal function, and degree of tubular atrophy and interstitial fibrosis at the time of biopsy. Interactome analysis showed the association of attenuated VEGF-A expression with the downregulation of genes that usually stimulate VEGF-A expression, such as epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), and HIF-2alpha. In vitro experiments confirmed the positive regulatory effect of EGF and IGF-1 on VEGF-A transcription in human proximal tubular cells. Thus, in progressive but not in stable proteinuric kidney disease, human PTECs show an attenuated VEGF-A expression despite an activation of intracellular hypoxia response and VEGF signaling pathways, which might be due to a reduced expression of positive coregulators, such as EGF and IGF-1.
- Published
- 2009
- Full Text
- View/download PDF
14. Kidney transplantation in patients suffering from hereditary complete complement C4 deficiency.
- Author
-
Falkeis C, Mark W, Sergi C, Heininger D, Neumair F, Scheiring J, and Lhotta K
- Subjects
- Adolescent, Adult, Child, Preschool, Female, Glomerulonephritis, Membranoproliferative complications, Glomerulonephritis, Membranoproliferative etiology, Humans, IgA Vasculitis complications, IgA Vasculitis etiology, Kidney Failure, Chronic etiology, Male, Middle Aged, Complement C4 deficiency, Genetic Diseases, Inborn complications, Kidney Failure, Chronic surgery, Kidney Transplantation
- Abstract
Hereditary complete C4 deficiency (C4def) is a very rare condition that predisposes to immune complex disease and end-stage renal failure. Whether such patients should undergo renal transplantation is debated. The clinical outcome of five transplantations in three C4def patients is described. The first patient lost one allograft after 6 years because of chronic allograft rejection. Back on dialysis, he suffered from meningitis caused by Neisseria menigitidis and Aspergillus. One year after a second transplantation under alemtuzumab induction, he developed fulminant Kaposi's sarcoma and died. His sister is now 6 years post-transplantation without complications. The third patient lost his first graft after 3 years because of chronic allograft nephropathy and recurrence of glomerulonephritis. He has now been living with a second graft for over 9 years. He suffered from pneumonia, a generalized varicella infection and Hemophilis parainfluenzae bronchitis. Patients with complete C4def are at increased risk for infection after kidney transplantation. Under certain precautions and with judicious use of immunosuppression, good long-term results are achievable.
- Published
- 2007
- Full Text
- View/download PDF
15. Role of alpha/beta and gamma/delta T cells in renal ischemia-reperfusion injury.
- Author
-
Hochegger K, Schätz T, Eller P, Tagwerker A, Heininger D, Mayer G, and Rosenkranz AR
- Subjects
- Animals, Gene Expression Regulation, Receptors, Antigen, T-Cell, alpha-beta metabolism, Receptors, Antigen, T-Cell, gamma-delta metabolism, Time Factors, CD4-Positive T-Lymphocytes metabolism, Kidney Diseases pathology, Receptors, Antigen, T-Cell, alpha-beta genetics, Receptors, Antigen, T-Cell, gamma-delta genetics, Reperfusion Injury metabolism, T-Lymphocyte Subsets
- Abstract
T cells have been implicated in the pathogenesis of renal ischemia-reperfusion injury (IRI). To date existing data about the role of the T cell receptor (Tcr) are contradictory. We hypothesize that the Tcr plays a prominent role in the late phase of renal IRI. Therefore, renal IRI was induced in alpha/beta, gamma/delta T cell-deficient and wild-type mice by clamping renal pedicles for 30 min and reperfusing for 24, 48, 72, and 120 h. Serum creatinine increased equally in all three groups 24 h after ischemia but significantly improved in Tcr-deficient animals compared with wild-type controls after 72 h. A significant reduction in renal tubular injury and infiltration of CD4+ T-cells in both Tcr-deficient mice compared with wild-type controls was detected. Infiltration of alpha/beta T cells into the kidney was reduced in gamma/delta T cell-deficient mice until 72 h after ischemia. In contrast, gamma/delta T cell infiltration was equal in wild-type and alpha/beta T cell-deficient mice, suggesting an interaction between alpha/beta and gamma/delta T cells. Data from gamma/delta T cell-deficient mice were confirmed by in vivo depletion of gamma/delta T cells in C57BL/6 mice. Whereas alpha/beta T cell-deficient mice were still protected after 120 h, gamma/delta T cell-deficient mice showed a "delayed wild-type phenotype" with a dramatic increase in kidney-infiltrating alpha/beta, Tcr-expressing CD4+ T-cells. This report provides further evidence that alpha/beta T cells are major effector cells in renal IRI, whereas gamma/delta T cells play a role as mediator cells in the first 72 h of renal IRI.
- Published
- 2007
- Full Text
- View/download PDF
16. p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury.
- Author
-
Hochegger K, Koppelstaetter C, Tagwerker A, Huber JM, Heininger D, Mayer G, and Rosenkranz AR
- Subjects
- Animals, Benzothiazoles pharmacology, Cyclin-Dependent Kinase Inhibitor p16 biosynthesis, Cyclin-Dependent Kinase Inhibitor p21 biosynthesis, Cyclin-Dependent Kinase Inhibitor p21 physiology, Kidney Diseases etiology, Kidney Diseases physiopathology, Male, Mice, Mice, Inbred C57BL, Reperfusion Injury prevention & control, Telomerase biosynthesis, Time, Toluene analogs & derivatives, Toluene pharmacology, Biomarkers analysis, Cyclin-Dependent Kinase Inhibitor p21 analysis, Ischemia diagnosis, Kidney Diseases diagnosis, Reperfusion Injury diagnosis, Telomerase analysis
- Abstract
In many clinical settings, the duration of renal ischemia and therefore the outcome of acute renal failure cannot be determined adequately. Renal ischemia reperfusion injury is known to shorten telomeres and upregulate stress-induced genes, such as the cyclin-dependent kinase (CDK) inhibitor p21. So far, the expression and role of CDK inhibitors, as well as mouse telomerase reverse transcriptase (mTERT), has not been investigated in a model with variable lasting ischemic periods. Male C57Bl/6 mice were subjected to renal ischemia reperfusion injury by clamping both renal pedicles for 10, 20, 30, and 45 min, and the kidneys were allowed to be reperfused for 3, 24, and 48 h. Expression of different CDK inhibitors and mTERT was evaluated. Mice developed signs of acute renal failure linear to the duration of the ischemic period. Real-time PCR revealed that mTERT was only significantly upregulated in kidneys after short ischemic periods (20 min). In contrast, p21 was constantly upregulated in kidneys after long ischemic intervals (30 and 45 min), but not in kidneys, which were clamped for shorter periods. Mainly, tubular cells contributed to the observed increase in p21 expression. Targeting p21 via the selective p53 inhibitor pifithrin-alpha was able to prevent acute renal failure when administered immediately before ischemia. The expression of another CDK inhibitor, namely p16, was differentially regulated, depending on the time of reperfusion. Taken together, we detected mTERT and p21 as "indicator" genes for short and long ischemic intervals, respectively. These two proteins might also be possible new therapeutic targets in the treatment and prevention of acute renal failure.
- Published
- 2007
- Full Text
- View/download PDF
17. Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis.
- Author
-
Hochegger K, Siebenhaar F, Vielhauer V, Heininger D, Mayadas TN, Mayer G, Maurer M, and Rosenkranz AR
- Subjects
- Animals, CD4-Positive T-Lymphocytes immunology, Disease Models, Animal, Lymph Nodes cytology, Lymph Nodes immunology, Macrophages immunology, Mice, Mice, Mutant Strains, RNA, Messenger analysis, Reverse Transcriptase Polymerase Chain Reaction, Serine Endopeptidases biosynthesis, Serine Endopeptidases immunology, Transforming Growth Factor beta immunology, Transforming Growth Factor beta metabolism, Transforming Growth Factor beta1, Tryptases, Anti-Glomerular Basement Membrane Disease immunology, Anti-Glomerular Basement Membrane Disease pathology, Mast Cells immunology
- Abstract
Recently, divergent reports on the role of mast cells (MC) in different glomerular diseases have brought our attention to their role in an accelerated model of anti-glomerular basement membrane (GBM) glomerulonephritis (GN). Genetically MC-deficient Kit(W)/Kit(W-v) mice, MC-reconstituted Kit(W)/Kit(W-v) mice and Kit+/+ control mice were subjected to anti-GBM GN. Kit(+/+) mice developed moderate proteinuria and glomerular damage following the induction of anti-GBM nephritis. In contrast, proteinuria and glomerular damage were dramatically increased in MC-deficient Kit(W)/Kit(W-v) mice. MC-reconstituted Kit(W)/Kit(W-v) mice showed proteinuria and glomerular damage comparable to Kit+/+ mice. A significant increase in infiltrating T cells and macrophages was detected in MC-deficient Kit(W)/Kit(W-v) mice as compared to Kit+/+ control mice and MC-reconstituted Kit(W)/Kit(W-v) mice. Accordingly, we observed an increase of TGF-beta1 mRNA in kidneys from Kit(W)/Kit(W-v) mice. Interestingly, we did not detect MC in the kidney using either Giemsa staining or RT-real-time PCR, but MC were found in the regional lymph nodes. Finally, mortality of Kit(W)/Kit(W-v) mice was significantly increased after the induction of anti-GBM GN due to uremia. Our report provides the first direct evidence that MC are protective in anti-GBM GN, possibly by modulating the influx of effector T cells and macrophages to inflammatory sites in the kidney.
- Published
- 2005
- Full Text
- View/download PDF
18. Severe electrolyte disturbances and renal failure in elderly patients with combined diuretic therapy including xipamid.
- Author
-
Sandhofer A, Kähler C, Heininger D, Bellmann R, Wiedermann CJ, and Joannidis M
- Subjects
- Age Factors, Aged, Aged, 80 and over, Diuretics administration & dosage, Drug Therapy, Combination, Emergencies, Female, Furosemide administration & dosage, Humans, Hydrochlorothiazide administration & dosage, Male, Risk Factors, Sodium Chloride Symporter Inhibitors administration & dosage, Xipamide administration & dosage, Diuretics adverse effects, Furosemide adverse effects, Hydrochlorothiazide adverse effects, Hypokalemia chemically induced, Hyponatremia chemically induced, Hypovolemia chemically induced, Sodium Chloride Symporter Inhibitors adverse effects, Uremia chemically induced, Xipamide adverse effects
- Abstract
Unlabelled: Diuretics are among the most frequently prescribed substances in elderly patients, but they are also associated with the highest incidence of adverse effects in this group of patients. Xipamide is a sulfonamide-like diuretic whose action does not depend on transtubular secretion. This characteristic makes it suitable for situations in which the kidney is highly sodium avid. Because of the potency of this substance the risk of adverse reactions like electrolyte disorders or hypovolemia is increased as well. We report seven patients (age 65-85) admitted to the emergency room of the University Hospital of Innsbruck between 1998 and 2002 who had developed serious adverse reactions upon initiation of treatment with xipamide as an additional diuretic. Six of these patients had received combinations with loop diuretics. The disturbances observed were hyponatremia (lowest value 108 mmol/l), hypokalemia (lowest value 1.5 mmol/l) and prerenal azotemia (highest serum urea 269 mg/dl, highest serum creatinine 5.13)., Conclusion: With the exception of diuretic resistance in severe heart failure or renal insufficiency a combination therapy of xipamide with a second diuretic appears to be associated with an unnecessarily high risk of serious adverse reactions and thus should be avoided. This is especially true for elderly patients.
- Published
- 2002
19. Importance of hepatic portal circulation for insulin action in streptozotocin-diabetic rats transplanted with fetal pancreases.
- Author
-
Brown J, Mullen Y, Clark WR, Molnar IG, and Heininger D
- Subjects
- Animals, Blood Glucose metabolism, Diuresis, Glycosuria therapy, Insulin blood, Insulin Secretion, Male, Rats, Streptozocin, Transplantation, Homologous, Diabetes Mellitus, Experimental therapy, Insulin metabolism, Liver Circulation, Pancreas Transplantation, Portal System physiology
- Abstract
The importance of the hepatic portal circulation in the response to insulin was assessed in streptozotocin-diabetic rats transplanted with syngeneic fetal pancreases. Partial reversal of diabetes was accomplished by transplantation of two or three fetal pancreases beneath the capsule of the kidney; complete reversal followed shunting of the venous drainage from the transplants to the liver. Plasma glucose after streptozotocin of 509+/-31 mg/dl (mean+/-SEM) fell after transplantation to 395+/-23 and after the shunt to 143+/-5 mg/dl. Urine volume fell from 84+/-4 to 50+/-5 ml/d and then to normal (17+/-1 ml/d) after the shunt. Glucose excretion which was 8.1+/-0.3 g/d after streptozotocin fell after transplantation to 4.8+/-0.3 g/d and after the shunt completely disappeared from the urine. The disappearance rate of glucose injected into the circulation, which was 0.50+/-0.07%/min in untreated diabetes, increased to 1.39+/-0.38%/min after transplantation and to 2.52+/-0.31%/min after the shunt, not different from normal controls (2.79+/-0.25). Plasma immunoreactive insulin (IRI) was below normal (25-35 muU/ml) and unresponsive to glucose in untreated diabetic rats. After transplantation IRI levels ranged from 73-223 muU/ml and there was no rise after glucose injection. After the shunt both the basal IRI (36+/-5 muU/ml) and the peak response to glucose at 10 min (58+/-7 muU/ml) were the same as in normal controls (42+/-4 and 62+/-7 muU/ml, respectively). The fall in IRI after the shunt is explained by increased extraction of insulin passing into the liver and also diminished secretion. After removal of the transplants plasma glucose and urine values returned almost to pretransplant levels. Secretion of insulin by transplanted pancreases into the liver enhances the effectiveness probably by increased extraction and action and reveals the importance of the normal route for insulin delivery.
- Published
- 1979
- Full Text
- View/download PDF
20. Activation of cytotoxic function in T lymphocytes.
- Author
-
Heininger D, Touton M, Chakravarty AK, and Clark WR
- Subjects
- Animals, Cell Separation, Concanavalin A pharmacology, Cytotoxicity Tests, Immunologic, DNA biosynthesis, Dose-Response Relationship, Immunologic, Immunologic Memory, Lymphocyte Culture Test, Mixed, Mice, Mice, Inbred C57BL, Mice, Inbred DBA, T-Lymphocytes immunology
- Abstract
The requirements for activation of cytotoxic function in mouse T lymphocytes were investigated. Initial generation of cytotoxicity in normal lymphocytes was equal in magnitude with either Con A or specific alloantigen, and in either case required DNA synthesis. Cytotoxic function in MLC-primed cells could also be regenerated by Con A, the magnitude and target specificity of the cytotoxicity thus generated being indistinguishable from that recalled by specific alloantigen. Cytotoxicity could also be regenerated by third party-stimulating cells; however, the cytotoxicity evoked by third party cells was always specific only for target cells of the original stimulating cell H-2 genotype. The data presented suggest that there are a number of ways to activate cytotoxicity in effector T cells, and are most consistent with a model for T cell triggering that minimizes a strict informational function of antigen-receptor interactions.
- Published
- 1976
21. Reversal of diabetes in rats using fetal pancreases stored at -196 C.
- Author
-
Kemp JA, Mullen Y, Weissman H, Heininger D, Brown J, and Clark WR
- Subjects
- Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Experimental metabolism, Female, Freezing, Glycosuria, Hyperglycemia complications, Insulin biosynthesis, Pregnancy, Rats, Rats, Inbred Lew, Transplantation, Homologous, Diabetes Mellitus, Experimental immunology, Fetus immunology, Organ Preservation, Pancreas Transplantation, Tissue Preservation
- Abstract
Fetal rat pancreases frozen to and stored at -196 C were used for transplantation into streptozotocin-induced diabetic syngeneic adult recipients. Transplantation was carried out either directly after thawing from -196 C, or after a 21-day growth period in a syngeneic, normoglycemic adult carrier. All transplants were placed under the kidney capsule. A single, frozen fetal rudiment was sufficient to restore blood glucose, urine volume, and urine glucose to normal, provided it had first been grown for 21 days in a normal carrier. It vitro perfusion studies showed that fetal pancreases stored at -196 C were equivalent to fresh rudiments in their responses to a glucose stimulus.
- Published
- 1978
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.